Galderma Group (GALD) Stock Overview

Operates as a dermatology company worldwide. More details

GALD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	3/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 26.9% below our estimate of its fair value

Earnings are forecast to grow 30.78% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

GALD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Galderma Group AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Galderma Group
Historical stock prices
Current Share Price	CHF 163.00
52 Week High	CHF 163.00
52 Week Low	CHF 149.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	7.24%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	GALD	AT Pharmaceuticals	AT Market
7D	7.9%	-2.1%	2.4%
1Y	n/a	-14.0%	28.5%

Return vs Industry: Insufficient data to determine how GALD performed against the Austrian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GALD performed against the Austrian Market.

Price Volatility

Is GALD's price volatile compared to industry and market?
GALD volatility
GALD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	4.7%
Market Average Movement	3.4%
10% most volatile stocks in AT Market	5.4%
10% least volatile stocks in AT Market	1.9%

Stable Share Price: GALD's share price has been volatile over the past 3 months compared to the Austrian market.

Volatility Over Time: Insufficient data to determine GALD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	6,545	Flemming Ornskov	www.galderma.com

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology.

Galderma Group AG Fundamentals Summary

How do Galderma Group's earnings and revenue compare to its market cap?
GALD fundamental statistics
Market cap	€38.65b
Earnings (TTM)	€328.18m
Revenue (TTM)	€4.07b

117.8x

P/E Ratio

9.5x

P/S Ratio

Is GALD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GALD income statement (TTM)
Revenue	US$4.69b
Cost of Revenue	US$1.44b
Gross Profit	US$3.25b
Other Expenses	US$2.87b
Earnings	US$378.00m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	1.59
Gross Margin	69.21%
Net Profit Margin	8.06%
Debt/Equity Ratio	35.2%

How did GALD perform over the long term?

See historical performance and comparison

Dividends

0.09%

Current Dividend Yield

10%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/03 01:46
End of Day Share Price	2025/11/03 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galderma Group AG is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yihan Li	Barclays
Fulvio Cazzol	Berenberg
Bethan Davies	Berenberg